Latest analyst takes
GenExDividendInvestorBULLJNJ is the kind of blue-chip dividend business that can be “safe” within a diversified portfolio because it should keep producing income, even though any single company can still face litigation or other shocks.9d agoGenExDividendInvestorBULLJohnson & Johnson (JNJ) earns a place in my portfolio for stability of shareholder payouts, paying roughly $5,200 per year on my ~$226k position.16d agoGenExDividendInvestorBULLI view JNJ as a high-quality, dividend-generating healthcare staple with roughly 2.2% yield and consensus ~9% earnings growth but concentrated exposure and litigation risk mean I’d stop adding new money and instead diversify future contributions.23d ago"JNJ is the kind of blue-chip dividend business that can be “safe” within a diversified portfolio because it should keep producing income, even though any single company can still face litigation or other shocks."
"Johnson & Johnson (JNJ) earns a place in my portfolio for stability of shareholder payouts, paying roughly $5,200 per year on my ~$226k position."
"I view JNJ as a high-quality, dividend-generating healthcare staple with roughly 2.2% yield and consensus ~9% earnings growth but concentrated exposure and litigation risk mean I’d stop adding new money and instead diversify future contributions."